



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Commissioner for Patents  
**MAIL STOP PATENT APPLICATION**

22389 U.S. PTO  
10/665365  
09/22/03

**TRANSMITTAL FOR A CONTINUATION-IN-PART APPLICATION  
UNDER 37 C.F.R. §1.53(b)**

This is a continuation-in-part application under 37 C.F.R. §1.53(b) from PCT International Application No. PCT/CA02/01810 filed November 29, 2002 for:

Inventors: Nirupama KARUNARATNE and Ken JOHNSON and Hiroki KANAYA

For: WHITE PEARLESCENT PAINT COMPOSITIONS AND COATINGS

1. This is a new  Utility  Design  Plant patent application.
2. The papers enclosed to obtain a filing date are as follows:

28 Pages of Specification including:  
0 Title Page  
25 Pages of Description  
2 Pages of Claims  
1 Page of Abstract  
12 Sheets of drawings containing 12 Figures  
 The enclosed drawings are photographs, and there is also attached a PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)

3. Combined Declaration and Power of Attorney

Enclosed and is executed by all inventors  
 Not Enclosed.

This application is being filed under the provisions of 37 C.F.R. §1.53(f). Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees.

## 4. Language

English

Non-English

This application is being filed in accordance with 37 C.F.R. §1.52(d) and §608.01 of the MPEP. Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the verified English translation and the processing fee.

## 5. Assignment

An assignment of the invention to \_\_\_\_\_ and a PTO Form-1595, Recordation Form Cover Sheet, are enclosed.

An assignment will be filed at a later date.

## 6. Priority - foreign applications under 35 U.S.C. §119(a)-(d) or §365(b) or PCT international applications under 35 U.S.C. §365(a) designating at least one country other than the U.S.

Priority of the following PCT application is claimed:

Application No.	Filed
PCT/CA02/01810	November 29, 2002

## 7. Priority based on provisional application(s) - 35 U.S.C. §119(e)

Priority of the following provisional application(s) is claimed:

Application No.	Filed
60/334,422	November 29, 2001

## 8. Small entity status

Applicant(s) hereby assert(s) small entity status under 37 C.F.R. § 1.27.

9. Fee Calculation (37 C.F.R. §1.16)

	Number Filed	Number Extra	at Rate of	Basic Fee
				Utility \$750.00 Design \$330.00
			BASIC FEE	\$750.00
Total Claims (37 C.F.R. §1.16(c))	18 - 20 =	0	18.00	
Independent Claims (37 C.F.R. §1.16(b))	2 - 3 =	0	84.00	
Multiple dependent claim(s), if any (37 C.F.R. §1.16(d))			280.00	\$280.00
				\$1030.00
			SUB-TOTAL =	
			Reduction by 1/2 for filing by a small entity	
			SUB-TOTAL =	\$1,030.00
Assignment Recordation Fee			\$40.00	
			TOTAL FILING FEE =	\$\$1,030.00

10. Fee Payment



**Not Enclosed. NO FEE IS BEING PAID BY CHECK OR DEPOSIT ACCOUNT AT THIS TIME.**

This application is being filed under the provisions of 37 C.F.R. §1.53(f). Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees.



Please charge Deposit Account No. 50-0310 in the amount of \$ representing the basic filing fee of \$750.00 and an assignment recording fee of \$40.00 is enclosed

11.



**Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).**

12. Additional papers enclosed:

- Preliminary Amendment
- Information Disclosure Statement
- Form PTO-1449, \_\_\_\_\_ document included
- Declaration of Biological Deposit
- Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

**Please accord this application an application number and filing date.**

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**

*Michael S. Tuscan*  
*Michael S. Tuscan*

*Reg No 43,210*

*fr* Paul N. Kokulis-Reg. No. 16,773

Dated: September 22, 2003

**Customer No. 09629**

MORGAN, LEWIS & BOCKIUS LLP  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
(202) 739-3000